All lobbying filings

MARSHALL & POPP, LLC

Lobbying for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · Pharmaceuticals.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 2

HAZEN CLAY MARSHALL

Previously held: Policy Director-Senate Majority Leader Mitch McConnell; Staff Director/Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP

Previously held: Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 6

Centers For Medicare and Medicaid Services (CMS)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Economic Council (NEC)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
HR 946
ORPHAN Cures Act

Lobbying activity 2

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.

Trade (domestic/foreign)

Issues related to tariff and trade policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.